Back to search

United States· US:68788-9899_ea0f64e0-dd40-456b-a1f5-2e501ee07e1e

Medroxyprogesterone Acetate

A medroxyprogesterone product containing medroxyprogesterone acetate, registered in United States by Preferred Pharmaceuticals, Inc.. The same ATC class is registered in 8 of our 19 countries.

ATC L02AB02Orange BookUS label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedMedroxyprogesterone AcetateATCL02AB02REGISTER NO.US:68788-9899_ea0f64e…PACKS LISTED2CHECKEDSeptember 12, 2026

Where it is registered

Medroxyprogesterone is registered in 8 of 19 countries.

Countries holding a registration under ATC L02AB02 (medroxyprogesterone), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 6 of them publish a price we can compare per daily dose

Medroxyprogesterone · ATC L02AB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of medroxyprogesterone costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Medroxyprogesterone · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$5.69
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
Medroxyprogesterone Acetate
Manufacturer
Preferred Pharmaceuticals, Inc.
Country
United States (US)
ATC code
L02AB02
ATC class
Medroxyprogesterone
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 12, 2026

Packs & prices · 2

  • ndc11
    6878898991
    10 TABLET in 1 BOTTLE (68788-9899-1)
  • ndc11
    6878898993
    30 TABLET in 1 BOTTLE (68788-9899-3)

Regulatory notes

UNII (FDA substance ID)
C2QI4IOI2G
MEDROXYPROGESTERONE ACETATE
RxCUI 1000112
Orange Book
A040159
ABABAB
DailyMed SPL labels
1 version tracked

Interactions

241 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Medroxyprogesterone · interactions on record

241 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Belgium · Depo-Provera, Provera
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • Finland · Farlutal, Provera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Norway · Depo-Provera, Provera
  • Poland · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d601b0af-bbe9-462c-9dcf-483f683c20ee
GET /v1/drugs/d601b0af-bbe9-462c-9dcf-483f683c20ee?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unii": {
    "unii": "C2QI4IOI2G",
    "rxcui": "1000112",
    "inchikey": "PSGAAPLEWMOORI-PEINSRQWSA-N",
    "display_name": "MEDROXYPROGESTERONE ACETATE",
    "substance_type": "chemical",
    "ingredient_type": "INGREDIENT SUBSTANCE"
  },
  "route": "ORAL",
  "livertox": {
    "summary": null,
    "livertox_id": null,
    "hepatotoxicity_score": 1
  },
  "spl_meta": {
    "1020bb60-4f13-4cd7-aaa1-c556752c84b7": {
      "match": "brand_token",
      "title": "MEDROXYPROGESTERONE ACETATE TABLET [REMEDYREPACK INC.]",
      "spl_version": "1",
      "published_date": "2026-05-28"
    }
  },
  "productid": "68788-9899_ea0f64e0-dd40-456b-a1f5-2e501ee07e1e",
  "productndc": "68788-9899",
  "dosage_form": "TABLET",
  "orange_book": {
    "appl_no": "040159",
    "products": [
      {
        "rs": false,
        "rld": false,
        "te_code": "AB",
        "strength": "2.5MG",
        "product_no": "001",
        "approval_date": "Aug 9, 1996"
      },
      {
        "rs": false,
        "rld": false,
        "te_code": "AB",
        "strength": "5MG",
        "product_no": "002",
        "approval_date": "Aug 9, 1996"
      },
      {
        "rs": false,
        "rld": false,
        "te_code": "AB",
        "strength": "10MG",
        "product_no": "003",
        "approval_date": "Aug 9, 1996"
      }
    ],
    "appl_type": "A"
  },
  "dea_schedule": null,
  "product_type": "HUMAN PRESCRIPTION DRUG",
  "substance_name": "MEDROXYPROGESTERONE ACETATE",
  "proprietary_name": "Medroxyprogesterone Acetate",
  "active_ingred_unit": "mg/1",
  "application_number": "ANDA040159",
  "marketing_category": "ANDA",
  "nonproprietary_name": "Medroxyprogesterone Acetate",
  "start_marketing_date": "20120213",
  "active_numerator_strength": "10"
}

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.